Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

Autor: Novik AV; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia. anovik@list.ru.; St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia. anovik@list.ru., Protsenko SA; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia., Baldueva IA; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.; I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia., Ivantsov AO; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia., Nekhaeva TL; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.; I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia., Akhaeva ZY; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia., Yanus GA; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia., Iyevleva AG; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia., Imyanitov EN; N.N. Petrov Research Institute of Oncology, Leningradskaya str. 68, Pesochny, St. Petersburg, 197758, Russia.; St. Petersburg Pediatric Medical University, St. Petersburg, 194100, Russia.; I.I. Mechnikov North-Western Medical University, St. Petersburg, 191015, Russia.; St. Petersburg State University, St. Petersburg, 199034, Russia.
Jazyk: angličtina
Zdroj: Targeted oncology [Target Oncol] 2016 Apr; Vol. 11 (2), pp. 235-8.
DOI: 10.1007/s11523-015-0384-7
Abstrakt: Vemurafenib, a specific inhibitor of mutated BRAF kinase, may activate wild-type BRAF and therefore induce squamous cell skin carcinomas in patients treated for melanoma. All vemurafenib clinical trials excluded patients with multiple primary malignant tumors; therefore, the action of this drug on concurrent BRAF wild-type malignancies remains insufficiently studied. We observed a patient, who was administered vemurafenib for BRAF mutation-containing melanoma, but experienced immediate relapse of previously controlled breast cancer disease. Interestingly, breast cancer lesions underwent regression soon after vemurafenib discontinuation. Therefore, caution must be taken while considering vemurafenib treatment for patients with multiple tumors.
Databáze: MEDLINE
Externí odkaz: